1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)
Bibliographic record
Abstract
Abstract Background Respiratory Syncytial Virus (RSV)-related disease poses an economic burden due to a substantial amount of health care utilization (HCU). RENOIR is a phase 3 global, multicenter, randomized, double-blinded, placebo-controlled study evaluating vaccine efficacy (VE) in adults ≥60 years of age during two RSV seasons in Northern and Southern Hemisphere countries (Argentina, Canada, Finland, Japan, Netherlands, South Africa, and USA) (NCT05035212). VE at the end of the first RSV surveillance season (EOS1) against ARI-RSV, Lower Respiratory Tract Illness (LRTI)-RSV with ≥2 symptoms (2+ LRTI-RSV), and LRTI-RSV with ≥3 symptoms (3+ LRTI-RSV) was 62.2% (44.4, 74.9), 65.1% (35.9, 82.0), and 88.9% (53.6, 98.7), respectively. Methods HCU data and concomitant corticosteroid or antibiotic use were collected during the RSV season for Acute Respiratory Illness (ARI) events (defined as more than 1 day of new or increased cough, nasal congestion/discharge, sore throat, wheezing, sputum production, or shortness of breath). A pre-planned analysis of HCU at EOS1 was performed to assess HCU among participants receiving RSVpreF vs. placebo. Results A higher proportion of RSV-associated HCU was associated with more severe symptoms (43.0%, 60.3%, and 75% for ARI-RSV, 2+ LRTI-RSV, and 3+ LRTI-RSV, respectively). Medically attended (MA) VE was similar to VE for all first-episode cases with MA ARI-RSV 65.1% (35.9, 82.0), MA 2+ LRTI-RSV 70.4% (33.0, 88.4), MA 3+ LRTI-RSV 84.6% (32.0, 98.3). Most RSV-associated HCU were outpatient visits, with more in the placebo arm. A higher proportion of placebo arm participants with RSV cases had an RSV-associated emergency room visit. For ARI-RSV, there were 3 hospitalizations in the placebo arm and none in the RSVpreF arm. The placebo arm had higher antibiotic (11.8 - 55.6% higher) or corticosteroid (2.8 – 44.4% higher) use compared to the RSVpreF arm for ARI- or LRTI-RSV events. Table 1 Vaccine Efficacy of RSVpreF Against First Episode of RSV Cases in the First RSV Season – Evaluable Efficacy Population Table 2 Healthcare Resource Utilization Associated With RSV Cases in the First RSV Season Table 3 Prespecified Category of Concomitant Medication Uses for RSV Cases in the First RSV Season Conclusion RSVpreF reduced overall HCU and antibiotic or corticosteroid treatment for RSV-associated illnesses. The highest VE among MA RSV-associated cases was for MA 3+ LRTI-RSV. These findings suggest that RSVpreF may reduce RSV-related healthcare needs in older adults, thus alleviating this burden on health systems. Disclosures Edward E. Walsh, MD, Icosavax: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Merck: Honoraria|Moderna: Advisor/Consultant|Pfizer: Grant/Research Support Kumar Ilangovan, MD, MSPH, MMCi, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Agnieszka Zareba, MD PhD, Pfizer: Employee|Pfizer: Stocks/Bonds|Pfizer: Stocks/Bonds Qin Jiang, PhD, Pfizer: Employee|Pfizer: Employee|Pfizer: Stocks/Bonds|Pfizer: Stocks/Bonds Gonzalo Pérez Marc, M.D., GSK: Grant/Research Support|Merck: Grant/Research Support|Moderna: Expert Testimony|Moderna: Grant/Research Support|Pfizer: Grant/Research Support Elliot N. DeHaan, MD, Pfizer: Employee|Pfizer: Stocks/Bonds Michael Patton, B.Sc., Pfizer Inc.: Employee|Pfizer Inc.: Stocks/Bonds Yanqing Kan, MS, Pfizer: Pfizer's employee|Pfizer: Stocks/Bonds Daniel P. Eiras, MD, MPH, Pfizer, Inc.: Stocks/Bonds Tarek Mikati, MD,MPH, Pfizer: Stocks/Bonds Elena Kalinina, PhD, Pfizer: Pfizer employee|Pfizer: Stocks/Bonds David Cooper, PhD, Pfizer, Inc.: Stocks/Bonds Annaliesa S. Anderson, PhD, Pfizer: Employee|Pfizer: Stocks/Bonds Kena A. Swanson, Ph.D., Pfizer: Employee|Pfizer: Stocks/Bonds William C. Gruber, MD, Pfizer, Inc.: Employee|Pfizer, Inc.: Stocks/Bonds Alejandra C. Gurtman, M.D., Pfizer: Employee|Pfizer: Stocks/Bonds Beate Schmoele-Thoma, MD, Pfizer: Stocks/Bonds
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".